Samsung Bioepis biosimilars sales in Europe fall 6.3% in Q1 - Pulse by Maeil Business News Korea
Biogen exits biosimilar JV with Samsung, raising $2.3bn | pharmaphorum
Samsung Bioepis says its trastuzumab biosimilar as safe, effective as original
Biogen of US might reap W2tr from Samsung Bioepis call option
SAMSUNG BIOEPIS
Samsung Bioepis | LinkedIn
Samsung Bioepis launches Ontruzant in Brazil
Samsung Biologics Completes Purchase Of Samsung Bioepis | Contract Pharma
PharmaBoardroom - Samsung Bioepis
Un medicament biosimilar al Enbrel dezvoltat de Samsung Bioepis a fost aprobat în SUA - 360medical.ro
Samsung Biologics acquires Samsung Bioepis joint venture for $2.3bn
Samsung Bioepis Brings Heat to Race for Anti-VEGF Biosimilars | Ophthalmology Innovation Source
Biogen launches first US biosimilar with Samsung Bioepis
Samsung Bioepis Racks Up More Awards for Its Biosimilar Packaging
Samsung Bioepis begins late stage clinical trial of ustekinumab biosimilar
Biogen to sell equity stake in Samsung Bioepis joint venture for up to $2.3B - Drug Discovery and Development
Samsung Bioepis (@SamsungBioepis) / Twitter
Mundipharma to commercialize Samsung Bioepis to biosimilars Into Hong
Samsung Bioepis Announces 24-week Interim Results from a Phase 3 Trial of SB11, Proposed Ranibizumab Biosimilar | Business Wire
Merck to develop biosimilars with Samsung-Biogen joint venture - PMLiVE
Company News | Newsroom | SAMSUNG BIOLOGICS
SAMSUNG BIOEPIS
